



For Immediate Release

TSX-V: CST

Outstanding shares: 60,261,136

## **Dr. Alan Shaw Joins CO<sub>2</sub> Solution's Board of Directors**

*Proven track record with Codexis and in biotechnology industry further strengthens Board of Directors*

**Quebec City, Quebec, February 17, 2010** – CO<sub>2</sub> Solution Inc. (“CO<sub>2</sub> Solution” or the “Company”) is very pleased to announce that Dr. Alan Shaw, Ph.D., President and Chief Executive Officer of Codexis, Inc., has joined its Board of Directors. In addition to representing Codexis, Inc. (“Codexis”) following its recent investment in the Company, Dr. Shaw brings increased scientific and business development expertise to the Board level as the Company moves towards the commercialization of its technology.

Dr. Shaw has served as President of Codexis since its inception and Chief Executive Officer since 2002. He has been a member of Codexis' board of directors since 2002. Prior to Codexis, Dr. Shaw was Head of New Business Development for Clariant and Managing Director for Lancaster Synthesis and prior to Clariant's acquisition of BTP plc, Chief Operating Officer of Archimica, the pharmaceutical chemicals division of BTP plc. From 1994 to 1999, he was with Chiroscience Group plc, most recently as Managing Director of the pharmaceutical services unit, Chirotech Technology Limited, and a member of the board of directors of Chiroscience Ltd. Earlier in his career, Dr. Shaw held various scientific and management positions for over 15 years at Imperial Chemical Industries PLC (ICI)/Zeneca. Dr. Shaw serves on the board of directors of BIO, the biotechnology industry trade association, and is chair of the BIO Industrial and Environmental Section. He holds a Ph.D. in chemistry from the University of Durham, England.

Commenting on the appointment, Evan Price, Chairman of the Board stated, “We are truly privileged to have Dr. Shaw join the Board of Directors. He will be a significant asset by providing valuable guidance for CO<sub>2</sub> Solution's growth, as evidenced by his impressive track record in the pharmaceuticals and biotech industries and notably with Codexis. We look forward to tapping his extensive expertise to further strengthen the Board's ability to support the development and commercial deployment of our technology.”

Dr. Shaw stated, “I am very pleased to be joining the Board of Directors following Codexis' recent investment in CO<sub>2</sub> Solution and our exclusive agreement in enzymatic carbon capture. We look forward to collaborating on the development of carbon capture technology.”

### **About CO<sub>2</sub> Solution**

Based in Quebec City, CO<sub>2</sub> Solution Inc. has developed a proprietary bio-technological platform for the efficient capture of carbon dioxide (CO<sub>2</sub>), the most important greenhouse gas (GHG), from power plants and other large stationary sources of emissions. The Company's technology platform exploits the natural power of a biocatalyst (enzyme), carbonic anhydrase, which functions within humans and other mammals to manage CO<sub>2</sub> during respiration. CO<sub>2</sub> Solution has successfully adapted the enzyme to function within an industrial environment, and thus has taken advantage of a biomimetic approach to CO<sub>2</sub> capture based on millions of years of evolution. The Company is commercializing its technology for coal fired power generation, the oil sands and other CO<sub>2</sub>-

intensive industries where a low-cost capture solution is key to meeting climate change legislation in a cost effective manner.

CO<sub>2</sub> Solution's technology platform is protected by several North American and European patents, including the use of carbonic anhydrase for CO<sub>2</sub> capture and release in a packed column system. News releases and additional information can be found at [www.co2solution.com](http://www.co2solution.com).

Contacts:

**CO<sub>2</sub> Solution:** Annie Chiasson, Director, Corporate Affairs, [annie.chiasson@co2solution.com](mailto:annie.chiasson@co2solution.com), 418-842-3456.

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***